No More Need for Dieting? AntiCancer’s Oral Methioninase Prevents Mouse Obesity and Diabetes on an Ultra-high-fat Diet

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. has announced that its methionine-cleaving enzyme methioninase prevented mice from becoming obese while on an ultra-high fat diet. Untreated mice on the ultra-high fat diet became obese.

Principal investigator Qinghong Han said, “With two oral doses of methioninase per day, dieting will not be necessary in the future, as the methioninase will control excess weight gain. Oral methioninase is being developed both as a pharmaceutical and supplement.”

The study appeared in the current issue at the journal In Vivo. First author Yoshihiko Tashiro said, “Methioninase not only prevents obesity but obesity-related diabetes as well. Unlike other treatments for these indications, oral methioninase has no side effects.”

AntiCancer has a pending broad patent application for oral methioninase for any indication. Methioninase is also effective against every type of cancer in mouse models and is proposed as treatment for coronavirus infection.

AntiCancer Inc. offers patient-derived orthotopic xenograft (PDOX) mouse models and HDRA 3-dimensional tumor culture for cancer drug discovery and optimal patient treatment; tumor targeting bacteria; pluripotent hair follicle stem cells which form neurons and other cell types for regenerative medicine and has pioneered tumor-specific fluorescence-guided surgery.

AntiCancer Inc. has headquarters in San Diego, with subsidiaries in Tokyo, Seoul, Beijing and Nanjing.

Follow AntiCancer at anticancer.com.